Contribute Try STAT+ Today

WASHINGTON — The federal government is spending more money on brand-name drugs for seniors in the Medicare Part D program, even as the number of prescriptions falls, a government watchdog report released Monday concluded.

The analysis, conducted by the Department of Health and Human Services Office of Inspector General, landed in Washington amid talks of radical changes to the Part D program, which typically covers drugs dispensed at a pharmacy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Supposed to happen that way. No other choices. Every drug even if it is not an orphan drug will be priced high to maintain the “C” suit lifestyle.

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy